Exicure, inc. and bluejay therapeutics inc. enter into a patent license agreement to develop cavrotolimod for the treatment of hepatitis

Chicago--(business wire)--exicure, inc., (nasdaq:xcur) a company that historically developed nucleic acid therapies, and bluejay therapeutics, inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases, announced today that bluejay therapeutics, inc. ("bluejay") and exicure, inc. ("exicure") entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis. under the terms of the agreement, bluejay will receive an exclusive l.
XCUR Ratings Summary
XCUR Quant Ranking